Lymphoma, Mantle-Cell  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00033267: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Completed
2
27
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
02/06
02/08
NCT00109967: CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Checkmark P2 data
Mar 2011 - Mar 2011: P2 data
Completed
2
71
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
09/09
03/12
NCT00787969: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark For initial therapy of mantle cell lymphoma
Jul 2014 - Jul 2014: For initial therapy of mantle cell lymphoma
Completed
1/2
74
US
rituximab, cladribine, temsirolimus, Filgrastim, Pegfilgrastim
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lymphoma
04/12
06/17
NCT01170052 / 2009-014844-13: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Withdrawn
1/2
20
Europe
Temsirolimus, Torisel®, Bendamustine
Charite University, Berlin, Germany, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma K.K.
Mantle Cell Lymphoma
04/12
04/14
NCT01389427: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Completed
1/2
41
Europe
Torisel dose 15 mg and R-CHOP, Arm A cohort -1, Torisel dose 15 mg and R-FC, Arm B cohort -1, Torisel dose 15 mg and R-DHA, Arm C cohort -1, Torisel dose 25 mg and R-CHOP, Arm A cohort 1, Torisel dose 50 mg and R-CHOP, Arm A cohort 2, Torisel dose 75 mg and R-CHOP, Arm A cohort 3, Torisel dose 25 mg and R-FC, Arm B cohort 1, Torisel dose 50 mg and R-FC, Arm B cohort 2, Torisel dose 75 mg and R-FC, Arm B cohort 3, Torisel dose 25 mg and R-DHA, Arm C cohort 1, Torisel dose 50 mg and R-DHA, Arm C cohort 2, Torisel 75 mg and R-DHA, Arm C cohort 3
The Lymphoma Academic Research Organisation, French Innovative Leukemia Organisation
Mantle Cell Lymphoma Refractory
05/15
09/15
BERT, NCT01078142 / 2009-013351-30: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark Interim P1/2 data in FL, MCL
Nov 2011 - Nov 2011: Interim P1/2 data in FL, MCL
Completed
1/2
39
Europe
Temsirolimus, Rituximab, Bendamustin, Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda
Georg Hess, MD, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma Pte Ltd.
Follicular Lymphoma, Mantle Cell Lymphoma
09/17
09/17

Download Options